Browsing by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
 

Showing results 45982 to 46001 of 206813 < previous   next >
WHO_OFFSET_60.pdf.jpg
Drug use among non-student youth / R. G. Smart ... [et al.]
Smart, Reginald George; Arif, Awni; Hughes, P. H; Medina Mora, Mar'ia Elena; Navaratnam, V; Varma, V. K; Wadud, K. A; World Health Organization ( 1981 )
emhj_1998_4_1_122_127.pdf.jpg
Drug use among prisoners in three main prisons in Khartoum, Sudan
Karim, El Fatih I.A. ( 1998 )
Abstract

Drug use among prisoners in the three main prisons in Khartoum, Sudan in 1994 was studied. The results show variations in the use of drugs with regard to age, occupation, education, marital status and social status of inmates. Drug use was common among most prisoners, with alcohol and hashish being the most frequently used drugs. Alcohol use was more common among married prisoners; hashish use was more popular among single prisoners. Alcohol was frequently used with other drugs. Most prisoners started using drugs between the ages of 12 and 20 years. The principal reasons for drug use were temptation by friends and to escape social pressures

E59334.pdf.jpg
Drug use and HIV-infection : the care of drug users and the treatment system / by Gerhard Buehringer [et al.]
Buehringer, Gerhard [et al.]; Greenwood, Judy; Gsellhofer, Brigitte; Kuenzel, Jutta; Torrens, Marta; World Health Organization. Regional Office for Europe ( 1998 )
Abstract

This report lists and discusses the changes that it will be necessary to make in the management of care for drug users as a consequence of AIDS. The purpose is to give practical information and guidelines to the administrators and senior staff responsible for prevention and care of problematic drug use, in order to meet the challenges posed by HIV infection. Management of care is used as a global term for all intervention strategies. It includes the different stages of primary prevention, early intervention and treatment of late stages, as well as different areas such as the treatment of drug use and of the HIV-related syndrome of diseases. The report covers the changes that will be necessary in care systems, including changes in the structure of facilities as well as in the care of the individual users

WHO-MSD-NVI-2016.01-eng.pdf.jpg
Drug use and road safety: a policy brief
World Health Organization ( 2016 )
WHO_PSA_93.3.pdf.jpg
Drug use and sport : current issues and implications for public health
Husch, Jerri A; World Health Organization. Programme on Substance Abuse ( 1993 )
Drug Use Epidemiology in Latin America and the Caribbean.pdf.jpg
Drug Use Epidemiology in Latin America and the Caribbean: A Public Health Approach
Pan American Health Organization ( 2009 )
Drug use in prisons in Kyrgyzstan: a study about the effect of health promotion among prisoners
Karymbaeva, S; van den Bergh, B J; Muratalieva, R; Moller, L F; Esenamanova, A ( 2008-01-01 )
Abstract

In Kyrgyzstan the prevalence of injecting drug behaviour is among the highest found throughout the world. Health promotion training, improved health care and needle/syringe exchange (NSE) programmes have been shown to decrease risk behaviour among injecting drug users. In Kyrgyzstan, an intervention study with training of prison staff and prisoners was performed in one prison. Before and after the training, a random selection of the prisoners answered a questionnaire about drug use, risk behaviour and health care. The survey was carried out in both the intervention prison and in a reference prison. The number of drug users, the use of drugs and risk behaviour were improved significantly within half a year and, especially, the injection and use of drugs decreased in the intervention group. The study clearly shows that increased focus, improved healthcare and training of prisoners and staff on drug use and harm reduction can reduce both use of drugs and risk behaviour.

emhj_1997_3_3_444_451.pdf.jpg
Drug utilization and antibiotic use in the primary health care centres in Sharjah
Hasan, Mohamed Yousif; Das, Mandira; Mourad, Fatema ( 1997 )
Abstract

Drug utilization and antibiotic use in the primary health care centres in Sharjah were studied before and after an intervention by the Antibiotics Control Committee. Prescriptions and patient records were reviewed and analysed based on World Health Organization methodology. Before intervention, the average number of drugs per prescription was 2.8, the average consultation time was 10.8 minutes, the average dispensing time was 89 seconds and 92% of visits resulted in a prescription, of which antibiotics constituted 45%. Following intervention, the percentage of prescriptions with antibiotics and the percentage of visits resulting in a prescription were significantly reduced

WHO_OFFSET_55.pdf.jpg
Drug-abuse reporting systems / I. Rootman, P. H. Hughes
Rootman, Irving; Hughes, P. H; World Health Organization ( 1980 )
26_4_2012.pdf.jpg
Drug-eluting stent approved for perpheral arterial disease
( 2012 )
17_2_2003.pdf.jpg
Drug-eluting stent for clogged heart arteries
( 2003 )
21_2_2007.pdf.jpg
Drug-eluting stents : to be used with caution
( 2007 )
22_4_2008.pdf.jpg
Drug-induced hyponatraemia
( 2008 )
Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field
Sagili, Karuna D; Anil, Singarajipura; Kulkarni, Sudhendra; Moonan, Patrick K; Akshatha, Jayachamarajapura S; Naik, Balaji; Buggi, Shashidhar; Volkmann, Tyson; Munivenkatappa, Somashekar; Chadha, Vineet K; Sharada, Manchenahalli A ( 2016-08-23 )
Abstract

We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ≥10 mIU/ml) during anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on anti-retroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.

WHO_MAL_82.978.pdf.jpg
Drug-resistant falciparum malaria cases imported from Dar Es Salam, United Republic of Tanzania / by E. Stahel, A. Degrémont, U. Lagler
Stahel, E; Degrémont, A; Lagler, U; World Health Organization ( 1982 )
16685_eng.pdf.jpg
Drug-resistant malaria : the report of a meeting, Kuala Lumpur, Malaysia, 10-15 August 1981 / held under the auspices of the World Health Organization Regional Offices for South-East Asia and the Western Pacific, and the Scientific Working Groups on the Chemotherapy of Malaria and on Applied Field Research in Malaria of the UNDP/WORLD BANK/WHO Special Programme for Research and Training in Tropical Diseases ; edited by Walter Wernsdorfer
Wernsdorfer, Walther H; UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases ( 1982 )
WHO_HQ_TB_2014.12_eng.pdf.jpg
Drug-resistant TB: surveillance and response: supplement to global tuberculosis report 2014
World Health Organization ( 2014 )
Drug-resistant tuberculosis : laboratory issues, World Health Organization recommendations / B. P. Vareldzis ... [et al.]
Vareldzis, Basil P; Grosset, Jacques; Crofton, Sir John; Laszlo, Adalbert; Felten, Michael; Raviglione, Mario C; Kochi, Arata; Kantor, Isabel N. de ( 1994 )
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
Mitnick, C D; Phillips, P; Thomas-Nyang'wa, B; Davies, G; du Cros, P; Nunn, A J; Merle, C; Wells, C; Furin, J; Nahid, P; Abubakar, I; Dooley, K E; Lienhardt, C; Diacon, A; Goolam-Mahomed, A; Dravnice, G; Nachman, S; Harrington, M; Harausz, E; McNeeley, D; Eisenach, K; Gupta, R; Fielding, K; Allen, E; Alirol, E; Dheda, K; Andersen, J; Ferstenberg, D; Grobusch, M P; Shah, S; Everitt, D; Horsburgh, C R; Rodriguez, C ( 2016-03-01 )
Abstract

Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new drugs have prompted strengthened efforts in DR-TB clinical trials research, and there are now multiple ongoing and planned DR-TB clinical trials. To facilitate comparability and maximise policy impact, a common set of core research definitions is needed, and this paper presents a core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work. To elaborate these definitions, a search of clinical trials registries, published manuscripts and conference proceedings was undertaken to identify groups conducting trials of new regimens for the treatment of DR-TB. Individuals from these groups developed the core set of definitions presented here. Further work is needed to validate and assess the utility of these definitions but they represent an important first step to ensure there is comparability in clinical trials on multidrug-resistant TB.

Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward
Ramsay, A; Dara, M; Acosta, C D; Dadu, A ( 2014-10-01 )
Abstract

Encouragingly, global rates of new tuberculosis (TB) cases have been falling since 2005, in line with the Millennium Development Goal targets; however, cases of multidrug-resistant (MDR-) and extensively drug-resistant TB (XDR-TB) have been increasing. Fifteen of the world's 27 high MDR- and XDR-TB burden countries are in the World Health Organization (WHO) European Region, of which 10 are in Eastern Europe (including Baltic and Caucasus countries). To address the MDR- and XDR-TB situation in the WHO European Region, a Consolidated Action Plan to Prevent and Combat M/XDR-TB (2011-2015) was developed for all 53 Member States and implemented in 2011. Since the implementation of the Action Plan, the proportion of MDR-TB appears largely to have levelled off among bacteriologically confirmed TB cases in high-burden countries with universal or near universal (>95%) first-line drug susceptibility testing (DST). The treatment success rate, however, continues to decrease. A contributing factor is the substantial proportion of MDR-TB cases that are additionally resistant to either a fluoroquinolone, a second-line injectable agent or both (XDR-TB); high-burden country proportions range from 12.6% to 80.4%. Proportions of XDR-TB range from 5% to 24.8%. Despite much progress in Eastern Europe, critical challenges remain as regards access to appropriate treatment regimens; patient hospitalisation; scale-up of laboratory capacity, including the use of rapid diagnostics and second-line DST; vulnerable populations; human resources; and financing. Solutions to these challenges are aligned with the Post-2015 Global TB strategy. As a first step, the global strategy should be adapted at regional and country levels to serve as a framework for immediate actions as well as longer-term ways forward.

Showing results 45982 to 46001 of 206813 < previous   next >